4. Benefit/risk balance of nanoparticle-based drugs

4.1 Concept of benefit/risk balance

As mentioned in the 2 section of this article, a drug can be formulated in a nanoparticle (encapsulation) or be the nanoparticle itself. For example, the aim is to:

improve or control bioavailability

You do not have access to this resource.

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed? Log in!

Ongoing reading
Benefit/risk balance of nanoparticle-based drugs

Previous
page Regulation of drugs containing nanoparticles

Conclusion

Article included in this offer

"Nanosciences and nanotechnologies"

( 135 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details

Bibliography

(1) - DU (B.), YU (M.), ZHENG (J.) - Transport and interactions of nanoparticles in the kidneys. - Nature Reviews Materials, 3(10) : p. 358-74 (2018).
(2) - COUVREUR (P.), FATTAL (E.), ANDREMONT (A.) - Liposomes and nanoparticles in the treatment of intracellular...

You do not have access to this resource.

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed? Log in!